Zenas BioPharma, Inc. GAAP EPS of -$4.54 misses by $3.66

ZENA is experiencing compounding fundamental deterioration: a GAAP EPS miss of -$4.54 against a stock price of $2.19 implies cash burn that dwarfs market capitalization on a per-share basis, signaling imminent dilution or financing risk. The 12-month price decline of -22.06% and current position at the absolute 5-year low of $2.19 confirm persistent institutional distribution with no technical floor established. Monthly volatility of 4.26% is deceptively low for a clinical-stage biotech, suggesting thin liquidity rather than price stability — a classic precursor to gap-down moves on negative catalysts. The sequential 6-period price erosion (2.33→2.19) with accelerating negative slope confirms bearish momentum with no visible accumulation pattern. ⚡ DEEP SONNET: Avoid new long positions entirely. For short exposure, optimal entry on any dead-cat bounce to the 2.27–2.36 resistance cluster, confirmed by failure to hold above 2.30 intraday. Do not chase short at current lows given gap-risk from surprise positive catalysts. | TP:22% SL:12% | 4–8 weeks, pending next financing or clinical update announcement | Risk:HIGH — Triple-layered risk: (1) Dilution risk is near-certain given EPS burn magnitude vs. share price; (2) Liquidity risk given thin trading implied by low volatility on a small-cap biotech; (3) Binary event risk from potential clinical readouts or FDA decisions that could cause 30–50% intraday moves in either direction. Short positions face short squeeze risk if pipeline news emerges unexpectedly. | Sizing:CONSERVATIVE